Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity.
NK
P-selectin
SLea/x
multiple myeloma
platelets
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Apr 2023
05 Apr 2023
Historique:
received:
20
02
2023
revised:
29
03
2023
accepted:
03
04
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Multiple myeloma (MM) is a plasma cell disorder that develops in the bone marrow (BM) and is characterized by uncontrolled proliferation and the ability to disseminate to different sites of the skeleton. Sialofucosylated structures, particularly Sialyl Lewis a/x (SLe
Identifiants
pubmed: 37046814
pii: cancers15072154
doi: 10.3390/cancers15072154
pmc: PMC10093642
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : 21198
Organisme : Italian Association for Cancer Research
ID : 800924
Organisme : Health Research Board
ID : CSA2012/10
Pays : Ireland
Références
Int J Cancer. 2016 May 1;138(9):2078-87
pubmed: 26356352
Immunol Rev. 2015 Jan;263(1):160-72
pubmed: 25510276
Glycobiology. 2018 Sep 1;28(9):648-655
pubmed: 29272415
Leukemia. 2017 Dec;31(12):2642-2651
pubmed: 28439107
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435306
Front Oncol. 2016 Apr 18;6:93
pubmed: 27148485
Blood Rev. 2001 Jun;15(2):61-7
pubmed: 11409906
Semin Cancer Biol. 2010 Jun;20(3):169-77
pubmed: 20452433
Cancer Res. 2012 Jan 15;72(2):440-8
pubmed: 22127925
Br J Haematol. 2021 Jan;192(2):322-332
pubmed: 32478420
Clin Exp Metastasis. 2014 Aug;31(6):697-704
pubmed: 24942131
Blood Adv. 2022 Jun 14;6(11):3352-3366
pubmed: 35294519
Cancer Cell. 2023 Feb 13;41(2):272-287.e9
pubmed: 36706761
FEBS J. 2006 Oct;273(19):4377-89
pubmed: 16956372
Br J Haematol. 2014 May;165(4):441-54
pubmed: 24580032
Cardiovasc Res. 2015 Aug 1;107(3):331-9
pubmed: 25994174
Biomed Res Int. 2015;2015:417586
pubmed: 26539491
Clin Cancer Res. 2018 May 15;24(10):2430-2439
pubmed: 29440174
PLoS One. 2019 Mar 25;14(3):e0211538
pubmed: 30908480
J Cell Biol. 2001 Jun 11;153(6):1277-86
pubmed: 11402070
Pharmacol Ther. 2016 Jan;157:112-9
pubmed: 26615781
Nat Rev Cancer. 2002 Mar;2(3):175-87
pubmed: 11990854
Cancers (Basel). 2019 Feb 19;11(2):
pubmed: 30791448
Expert Rev Anticancer Ther. 2008 Aug;8(8):1247-55
pubmed: 18699763
Front Oncol. 2022 Jul 01;12:941437
pubmed: 35847862
Haematologica. 2020 Jan 31;105(2):457-467
pubmed: 31101754
Mol Cell Oncol. 2020 May 21;7(4):1766338
pubmed: 32944626
J Immunol Methods. 2012 Oct 31;384(1-2):43-50
pubmed: 22820001
Leukemia. 2014 Feb;28(2):384-390
pubmed: 23817176
Blood. 2012 Feb 9;119(6):1468-78
pubmed: 22096244
Cancer Cell. 2017 Sep 11;32(3):282-293
pubmed: 28898694
Cancer Med. 2013 Aug;2(4):564-70
pubmed: 24156029
J Biol Chem. 2001 Dec 14;276(50):47623-31
pubmed: 11591704
Front Oncol. 2021 Mar 15;11:642761
pubmed: 33791226
Curr Osteoporos Rep. 2017 Oct;15(5):499-506
pubmed: 28889371